A 3-year, multi-center study to describe the long term changes of opti
A 3-year, multi-center study to describe the long term changes of optical coherence tomography (OCT) parameters in patients under treatment with Gilenya®
What was tested
Treatment tested
What it measured
Main measures
To evaluate the change in average RNFL thickness (RNFLT) in RRMS patients treated with fingolimod over 36 months as assessed by OCT.
Retina scans (OCT)
Other measures (1)
To evaluate the change in average RNFLT under fingolimod therapy from baseline to months 12 and 24 as assessed by OCT.
Retina scans (OCT)
Loading reviews and guidelines…
Related trials
- A Study to Learn About the Safety of Diroximel Fumarate (DRF) and Dime
Phase 3 · Not yet recruiting
Still running
- Study to Assess Effects of Ublituximab in Pediatric Participants With
Phase 2 / Phase 3 · Recruiting
Still running
- Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to
Phase 3 · Recruiting
Still running
- Prospective Evaluation of Sequencing From antiCD-20 Therapies to Ozani
Phase 4 · Recruiting
Still running
- Assessing the Cognitive Benefits of Ozanimod and Their Brain-Biomarker
Phase 4 · Withdrawn
Stopped
- A Study to Assess the Effectiveness and Safety of Ozanimod in Chinese
Phase 4 · Running, not recruiting
Still running
History
- In scope changed from true to false
Started
Apr 2012
Assembled by software from public sources.